MIRA1a Therapeutics

MIRA1a Therapeutics, alternately known as MIRA Pharmaceuticals, is a drug development company whose work draws from research by chief science officer and cofounder Adam Kaplin, a faculty member at Johns Hopkins University School of Medicine. Its namesake signature product, MIRA1a, is a drug under development for chronic pain that aims to replicate cannabis’s painkilling properties without negative side effects.